Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now displays a generic error screen indicating the requested record is unavailable, replacing the usual study details with an error notice.SummaryDifference19%

- Check24 days agoChange DetectedThe study record shows the status updated to Terminated on 2026-07-28 with a Business Reason indicating no longer looking for participants, replacing the prior Completed status.SummaryDifference0.2%

- Check31 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This reflects a new entry in the study page's revision history.SummaryDifference0.1%

- Check38 days agoChange DetectedThe study record now indicates completion and recruitment is closed. Enrollment has ended and no new participants will be enrolled.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, representing a minor update to the site. No user-facing content changes are indicated in the provided context.SummaryDifference0.0%

- Check59 days agoChange Detected- Revision label updated from v3.6.0 to v3.6.2, indicating a new page build. The change does not modify study content or data displayed on the page.SummaryDifference0.0%

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.